Drug intelligence / Profile preview

TRK-750

Development stage: Phase 1
Lead developer: Toray Industries
Modality: Small Molecules
Administration: Oral

Overview

TRK-750 is an orally available small molecule drug developed by Toray Industries for the treatment of peripheral neuropathic pain, particularly chemotherapy-induced peripheral neuropathy (CIPN) in patients with colorectal cancer. It has demonstrated analgesic effects in laboratory tests without notable central nervous system adverse effects. The precise mechanism of action remains undefined or unknown. Clinical development included Phase I and II studies assessing safety, tolerability, pharmacokinetics, and efficacy in both healthy volunteers and patients with peripheral neuropathic pain. As of the latest updates, development has been discontinued after reaching Phase II trials[1][2][3][5][7].

Other names: TRK 750TRK750TRK-750

Beyond the preview

Go deeper on TRK-750.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRK-750.

Explore the full profile